[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597077":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":21,"locations":27,"responsibleParty":178,"collaborators":180,"id":183,"slug":184,"hasResults":185,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":185,"sex":191,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":11,"studyType":197,"phases":198,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},{"fullName":5,"class":6},"Autolus Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Obe-cel","EXPERIMENTAL",null,[13],"Biological: Obecabtagene autoleucel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Obecabtagene autoleucel","Obecabtagene autoleucel (obe-cel) given as a single infusion",[9],[9],[22],{"name":23,"role":24,"phone":25,"phoneExt":11,"email":26},"Autolus Ltd","CONTACT","+44 (0)203 911 4385","clinicaltrials@autolus.com",[28,41,50,60,72,83,92,106,118,130,142,154,163,169],{"facility":29,"status":30,"city":31,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":11},"Icahn School of Medicine at Mount Sinai","RECRUITING","New York","10029","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-74.00597,40.71427,{"lat":39,"lon":38},{"facility":42,"status":30,"city":43,"state":31,"zip":44,"country":33,"countryCode":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":11},"State University of New York Upstate Medical Center (SUNY)","Syracuse","13210",{"type":36,"coordinates":46},[47,48],-76.14742,43.04812,{"lat":48,"lon":47},{"facility":51,"status":30,"city":52,"state":53,"zip":54,"country":33,"countryCode":34,"cosmosGeoPoint":55,"geoPoint":59,"contacts":11},"Texas Transplant Institute","San Antonio","Texas","78229",{"type":36,"coordinates":56},[57,58],-98.49363,29.42412,{"lat":58,"lon":57},{"facility":61,"status":30,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":11},"Instituto D´Or de Pesquisa e Ensino - Hospital São Rafael","Salvador","Estado de Bahia","41253-190","Brazil","BR",{"type":36,"coordinates":68},[69,70],-38.49096,-12.97563,{"lat":70,"lon":69},{"facility":73,"status":30,"city":74,"state":11,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":11},"University General Hospital ATTIKON","Athens","12461","Greece","GR",{"type":36,"coordinates":79},[80,81],23.72784,37.98376,{"lat":81,"lon":80},{"facility":84,"status":30,"city":85,"state":11,"zip":86,"country":76,"countryCode":77,"cosmosGeoPoint":87,"geoPoint":91,"contacts":11},"University General Hospital of Patras","Pátrai","26504",{"type":36,"coordinates":88},[89,90],21.73508,38.2462,{"lat":90,"lon":89},{"facility":93,"status":30,"city":94,"state":11,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Queen Elizabeth Hospital Birmingham","Birmingham","B15 2TH","United Kingdom","UK",{"type":36,"coordinates":99},[100,101],-1.89983,52.48142,{"lat":101,"lon":100},[104],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":105},"UHBHaematologyResearchTeam@uhb.nhs.uk",{"facility":107,"status":30,"city":108,"state":11,"zip":109,"country":96,"countryCode":97,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Bristol Haematology and Oncology Centre","Bristol","BS1 3LH",{"type":36,"coordinates":111},[112,113],-2.59665,51.45523,{"lat":113,"lon":112},[116],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":117},"BHOCClinicalTrials@uhbw.nhs.uk",{"facility":119,"status":30,"city":120,"state":11,"zip":121,"country":96,"countryCode":97,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Addenbrooke's Hospital","Cambridge","CB2 0QQ",{"type":36,"coordinates":123},[124,125],0.11667,52.2,{"lat":125,"lon":124},[128],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":129},"fatemeh.alemi@nhs.net",{"facility":131,"status":30,"city":132,"state":11,"zip":133,"country":96,"countryCode":97,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Western General Hospital Edinburgh","Edinburgh","EH4 2XU",{"type":36,"coordinates":135},[136,137],-3.19648,55.95206,{"lat":137,"lon":136},[140],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":141},"loth.rdoffice@nhs.scot",{"facility":143,"status":30,"city":144,"state":11,"zip":145,"country":96,"countryCode":97,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Queen Elizabeth University Hospital","Glasgow","G51 4TF",{"type":36,"coordinates":147},[148,149],-4.25763,55.86515,{"lat":149,"lon":148},[152],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":153},"ggc.glasgowcrf.generic@nhs.scot",{"facility":155,"status":30,"city":156,"state":11,"zip":157,"country":96,"countryCode":97,"cosmosGeoPoint":158,"geoPoint":162,"contacts":11},"University College Hospital","London","MW1 2PG",{"type":36,"coordinates":159},[160,161],-0.12574,51.50853,{"lat":161,"lon":160},{"facility":164,"status":30,"city":156,"state":11,"zip":165,"country":96,"countryCode":97,"cosmosGeoPoint":166,"geoPoint":168,"contacts":11},"Great Ormond Street Hospital","WC1N 3JH",{"type":36,"coordinates":167},[160,161],{"lat":161,"lon":160},{"facility":170,"status":30,"city":171,"state":11,"zip":172,"country":96,"countryCode":97,"cosmosGeoPoint":173,"geoPoint":177,"contacts":11},"Manchester Royal Infirmary","Manchester","M13 9WL",{"type":36,"coordinates":174},[175,176],-2.23743,53.48095,{"lat":176,"lon":175},{"type":179,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[181],{"name":182,"class":6},"PPD Development, LP","100597077","phase-2-obe-cel-in-severe-refractory-systemic-lupus-erythematosus-sle-with-active-lupus-nephritis-ln-100597077",false,"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)","A Single-Arm, Open-Label, Phase II Study to Determine the Safety and Efficacy of Obecabtagene Autoleucel (Obe-cel) in Participants With Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis","LUMINA","Inclusion Criteria:\n\n* Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative\n* Ability and willingness to adhere to protocol's Schedule of Activities and other requirements\n* Participants must be 12 to 65 years of age inclusive at the time of signing the informed consent.\n* Female Participants: - a female participant is eligible to participate if she is not pregnant or breastfeeding\n* Diagnosis of SLE fulfilling the 2019 European League Against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus.\n* Positive for at least 1 of the following autoantibodies: antinuclear antibodies (ANA), or anti-dsDNA or anti-Smith.\n* Severe, Active SLE defined as:\n\n  * SLEDAI-2K score of ≥ 8 points AND\n  * Severe active LN based on a renal biopsy: Class III, IV or V (V only in combination with class III or IV)\n* Refractory SLE defined as failure to previous lines of therapy\n\nExclusion Criteria:\n\n* Prior treatment at any time with anti-CD19 therapy\n* More than 1 acute, severe lupus-related flare during screening that needs immediate treatment and\u002For makes the immunosuppressive washout impossible\n* Significant, likely irreversible organ damage related to SLE (e.g., end-stage renal disease) that in the opinion of the Investigator renders CD19 CAR T cell therapy unlikely to benefit the participant\n* History of primary antiphospholipid antibody syndrome\n* Active or uncontrolled fungal, bacterial, or viral infection\n* History of malignant neoplasms unless disease free for at least 24 months\n* History of heart, lung, renal, liver transplant or hematopoietic stem cell transplant","ALL","12 Years","65 Years",{"count":195,"type":196},35,"ESTIMATED","INTERVENTIONAL",[199],"PHASE2","The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).",[202],"Lupus Nephritis",[204,205,206,17,9],"Systemic lupus erythematosus","Refractory systemic lupus erythematosus","Lupus nephritis","2026-07-30",{"date":209,"type":210},"2026-07-31","ACTUAL",{"date":212,"type":210},"2026-01-16",{"date":214,"type":196},"2029-10",{"name":5,"class":6},14]